Company Info

Phone
(732) 590-2900

Year Established
1991

Ticker
OXUR

Exchange
Euronext Brussels

Contacts

Tom Graney, CFA
CEO

Micha�l Dillen
CBO

Kathleen Paisley
CLO & General Counsel

Andy De Deene, MD, MBA
CDO

Company Description

Oxurion, formerly ThromboGenics, is a biopharmaceutical company focused on developing novel treatments for back of the eye diseases with an innovative pipeline in diabetic eye disease.